- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07244211
Protocolo MAPT: Tratamientos Quirúrgicos de Fijación versus Artroplastia para la Recuperación Temprana Después de una Fractura de CADERA (FASTER-HIP) (FASTER-HIP)
Ensayo de Plataforma Adaptativa Musculoesquelética (MAPT): Tratamientos Quirúrgicos de Fijación Versus Artroplastia para una Recuperación Temprana Después de una Fractura de CADERA (FASTER-HIP)
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.
Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.
FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Joseph Patterson, MD
- Número de teléfono: +13234426984
- Correo electrónico: OrthoTraumaResearch@med.usc.edu
Ubicaciones de estudio
-
-
-
Ottawa, Canadá, K1H 8L6
- Aún no reclutando
- The Ottawa Hospital
-
Contacto:
- Bradley Meulenkamp, MD
- Correo electrónico: bmeulenkamp@toh.ca
-
Investigador principal:
- Bradley Meulenkamp, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6T 1Z4
- Reclutamiento
- University of British Columbia
-
Contacto:
- Aresh Sepehri, MD
-
Contacto:
- Correo electrónico: aresh.sepehri@vch.ca
-
Investigador principal:
- Aresh Sephri, MD
-
Vancouver, British Columbia, Canadá
- Reclutamiento
- Fraser Health Authority
-
Contacto:
- Darius Viskontas, MD
- Número de teléfono: 604-777-5577
- Correo electrónico: dariusviskontas@yahoo.ca
-
Contacto:
- Número de teléfono: 604-777-5577
-
Investigador principal:
- Darius Viskontas, MD
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9,
- Reclutamiento
- London Health Sciences Centre
-
Contacto:
- Emil Schemitsch, MD
- Correo electrónico: emil.schemitsch@lhsc.on.ca
-
Investigador principal:
- Emil Schemitsch, MD
-
-
-
-
-
Barcelona, España
- Aún no reclutando
- Hospital Universitari Vall d'Hebron
-
Contacto:
- Carlos Alberto Piedra-Calle, MD
- Correo electrónico: carlosalberto.piedra@vallhebron.cat
-
Investigador principal:
- Carlos Alberto Piedra-Calle, MD
-
Barcelona, España
- Aún no reclutando
- Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
-
Investigador principal:
- Alfred Dealbert, MD
-
Contacto:
- Alfred Dealbert Dealbert, MD
- Correo electrónico: adealbert@csapg.cat
-
Barcelona, España, 08221
- Aún no reclutando
- Hospital Universitario Mutua de Terrassa
-
Contacto:
- Pablo Castillon Bernal, MD
- Correo electrónico: pablocastillon@mutuaterrassa.es
-
Investigador principal:
- Pablo Castillon Bernal, MD
-
Barcelona, España
- Aún no reclutando
- FRCB-IDIBAPS (Hospital Clinic Barcelona)
-
Contacto:
- Pilar Camacho, MD
- Correo electrónico: PCAMACHO@clinic.cat
-
Investigador principal:
- Pilar Camacho, MD
-
-
-
-
California
-
Irvine, California, Estados Unidos, 92660
- Reclutamiento
- University of California, Irvine
-
Investigador principal:
- Gerard Slobogean, MD
-
Contacto:
- Gerard Slobogean, MD
- Número de teléfono: 714-456-1699
- Correo electrónico: gsloboge@hs.uci.edu
-
Los Angeles, California, Estados Unidos, 90048
- Reclutamiento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Carol Lin, MD
-
Contacto:
- Carol Lin, MD
- Correo electrónico: carol.lin@cshs.org
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- University of Southern California
-
Investigador principal:
- Joshua L Gary, MD
-
Contacto:
- Joshua Gary, MD
- Número de teléfono: +13234426984
- Correo electrónico: OrthoTraumaResearch@med.usc.edu
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- Los Angeles General Medical Center
-
Investigador principal:
- Joshua L Gary, MD
-
Contacto:
- Joshua Gary, MD
- Número de teléfono: +13234426984
- Correo electrónico: OrthoTraumaResearch@med.usc.edu
-
San Francisco, California, Estados Unidos, 94143
- Reclutamiento
- University of California San Francisco
-
Investigador principal:
- Saam Morshed, MD
-
Contacto:
- Saam Morshed, MD
- Correo electrónico: Saam.morshed@ucsf.edu
-
-
Florida
-
Miami, Florida, Estados Unidos, 33146
- Aún no reclutando
- University of Miami
-
Contacto:
- Giselle Hernandez, MD
- Correo electrónico: g.hernandez@med.miami.edu
-
Investigador principal:
- Giselle Hernandez, MD
-
-
Indiana
-
Bloomington, Indiana, Estados Unidos, 47405
- Reclutamiento
- Indiana University
-
Investigador principal:
- Dillon O'Neill, MD
-
Contacto:
- Dillon O'Neill, MD
- Correo electrónico: doneill5@iuhealth.org
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Reclutamiento
- University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
-
Investigador principal:
- Mark Gage, MD
-
Contacto:
- Mark Gage, MD
- Correo electrónico: mgage@som.umaryland.edu
-
Largo, Maryland, Estados Unidos, 20774
- Reclutamiento
- University of Maryland Capital Region Health
-
Investigador principal:
- Todd Jaeblon, MD
-
Contacto:
- Todd Jaeblon, MD
- Correo electrónico: tjaeblon@som.umaryland.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Aún no reclutando
- Beth Israel Deaconess Medical Center
-
Contacto:
- Ishaq Ibrahim, MD
- Correo electrónico: ioibrahi@bidmc.harvard.edu
-
Investigador principal:
- Ishaq Ibrahim, MD
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Massachusetts General Brigham
-
Contacto:
- Michael Weaver, MD
- Correo electrónico: MJWEAVER@BWH.HARVARD.EDU
-
Investigador principal:
- Michael Weaver, MD
-
-
Mississippi
-
University, Mississippi, Estados Unidos, 38677
- Reclutamiento
- University of Mississippi
-
Investigador principal:
- Patrick Bergin, MD
-
Contacto:
- Patrick Bergin, MD
- Correo electrónico: pbergin@umc.edu
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Health
-
Investigador principal:
- Ran Schwarzkopf, MD
-
Contacto:
- Daniel Waren
- Correo electrónico: Daniel.waren@nyulangone.org
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45221
- Reclutamiento
- University of Cincinnati
-
Contacto:
- Michael Beltran, MD
- Correo electrónico: beltrame@ucmail.uc.edu
-
Investigador principal:
- Michael Beltran, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- University of Oklahoma Health Sciences Center
-
Investigador principal:
- Brandon Hull, MD
-
Contacto:
- Brandon Hull, MD
- Correo electrónico: Brandon-Hull@ou.edu
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18102
- Reclutamiento
- St. Luke's University Health System
-
Investigador principal:
- Dustin Greenhill, MD
-
Contacto:
- Dustin Greenhill, MD
- Correo electrónico: dustin.greenhill@sluhn.org
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29601
- Reclutamiento
- Prisma Health-Upstate
-
Investigador principal:
- Kyle Jeray, MD
-
Contacto:
- Kyle Jeray, MD
- Correo electrónico: kyle.jeray@prismahealth.org
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37235
- Reclutamiento
- Vanderbilt University
-
Contacto:
- Lauren Tatman, MD
- Correo electrónico: lauren.m.tatman@vumc.org
-
Investigador principal:
- Lauren Tatman, MD
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- Reclutamiento
- University of Utah
-
Investigador principal:
- Lucas Marchand, MD
-
Contacto:
- Lucas Marchand, MD
- Correo electrónico: lucas.marchand@hsc.utah.edu
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Aún no reclutando
- University of Vermont
-
Contacto:
- Michael Blankstein, MD
- Correo electrónico: michael.blankstein@uvmhealth.org
-
Investigador principal:
- Michael Blankstein, MD
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Inova Health Care Services
-
Investigador principal:
- Greg Gaski, MD
-
Contacto:
- Grag Gaski, MD
- Correo electrónico: greg.gaski@inova.org
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53706
- Reclutamiento
- University of Wisconsin - Madison
-
Investigador principal:
- Chris Domes, MD
-
Contacto:
- Chris Domes, MD
- Correo electrónico: domes@ortho.wisc.edu
-
-
-
-
-
Grålum, Noruega, 1714
- Reclutamiento
- Sykehuset Østfold HF / Østfold Hospital Trust
-
Contacto:
- Frede Frihagen, MD
-
Contacto:
- Correo electrónico: Frede.Frihagen@so-hf.no
-
Investigador principal:
- Frede Frihagen, MD
-
-
-
-
-
Edinburgh, Reino Unido, EH8 8BG
- Aún no reclutando
- University of Edinburgh
-
Contacto:
- Andrew Duckworth, MD
- Correo electrónico: andrew.duckworth@ed.ac.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
- The patient has a health condition affecting physical mobility.
- Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
- Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
- Low energy injury mechanism.
- Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.
Exclusion Criteria:
- The patient is not clinically suitable for either compared treatment.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Incarceration.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because the legally authorized representative was unavailable.
- Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
- Currently enrolled in a study or intervention domain that does not permit co-enrollment.
- Prior enrollment in the specific platform trial intervention domain.
- Patient or legally authorized representative did not provide informed consent (declined participation).
- Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
- Other reasons to exclude the patient, as approved by the data coordinating center.
- Associated lower extremity injury that prevents post-operative weight-bearing.
- Retained hardware around the hip that precludes either study treatment.
- Infection around the hip (soft tissue or bone).
- Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
- Injury did not occur within 21 days of screening.
- Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
- Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Artroplastia de cadera
|
Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon. |
|
Comparador activo: Fijación interna
|
Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
Periodo de tiempo: 120 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
Periodo de tiempo: 365 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
365 days after randomization
|
|
Death
Periodo de tiempo: 120 days post-randomization
|
Death consists of time to all-cause mortality. |
120 days post-randomization
|
|
Death
Periodo de tiempo: 12 months post-randomization
|
Death consists of time to all-cause mortality. |
12 months post-randomization
|
|
Ambulation status
Periodo de tiempo: 120 days post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
120 days post-randomization
|
|
Ambulation status
Periodo de tiempo: 12 months post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
12 months post-randomization
|
|
Days alive and out of hospital
Periodo de tiempo: 120 days post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days post-randomization
|
|
Days alive and out of hospital
Periodo de tiempo: 12 months post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
12 months post-randomization
|
|
Health-related quality of life
Periodo de tiempo: 120 days days post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
120 days days post-randomization
|
|
Health-related quality of life
Periodo de tiempo: 12 months post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
12 months post-randomization
|
|
Numeric Pain Rating Scale
Periodo de tiempo: During hospitalization in the first seven postoperative days
|
The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain |
During hospitalization in the first seven postoperative days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joseph T Patterson, MD, University of Southern California
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Heridas y Lesiones
- Lesiones en las piernas
- Fracturas, Hueso
- Lesiones de cadera
- Fracturas Femorales
- Fracturas de cadera
- Fracturas del cuello femoral
- Terapéutica
- Procedimientos quirúrgicos, operativo
- Artroplastia, reemplazo
- Artroplastia
- Procedimientos ortopédicos
- Procedimientos de cirugía plástica
- Implantación de prótesis
- Fijación de fractura
- Artroplastia, reemplazo, cadera
- Fijación de fractura, interna
Otros números de identificación del estudio
- BPS-2024C1-37436
- BPS-2024C1-37436 (Otro número de subvención/financiamiento: Patient-Centered Outcomes Research Institute)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .